Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 42, Issue , 1998, Pages

  Sausville, Edward A ^a   Lush, Richard D ^a   Headlee, Donna ^a   Smith, Adaline C ^a   Figg, William D ^a   Arbuck, Susan G ^a   Senderowicz, Adrian M ^a   Fuse, Eiichi ^b   Tanii, Hiromi ^b   Kuwabara, Takashi ^b   Kobayashi, Satoshi ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Protein kinase antagonist; Staurosporine, 7 hydroxy; 1 Acidic glycoprotein

Indexed keywords

7 HYDROXYSTAUROSPORINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PROTEIN BINDING; FLUORESCENCE; HUMAN; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL; XENOGRAFT;

EID: 0031672099     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051080     Document Type: Conference Paper

References (13)

1. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and tumor models. Cancer Res 51:4888
2. Akiyama T, Yoshida T, Tetsuya T, Shimizu M, Mizukami T, Okabe M, Akinaga S (1997) Gi phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/ Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57:1495
3. Bunch RT, Eastman A (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new 62-checkpoint inhibitor. Clin Cancer Res 2:791
4. Bunch RT, Eastman A (1997) 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 7:779
5. Hill DL, Tillery KF, Rose LM, Posey CF (1994) Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. Cancer Chemother Pharmacol 35:89
6. Kremer JMH, Wilting J, Janssen LHM (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1
7. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. In Teicher B (ed) Anticancer drug development guide. Humana, Totowa, NJ, p 101
8. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ (1993) Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53:2081
9. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville E, Worland P (1994) Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45:1207
10. Takahashi I, Kobayashi E, Nakano H, Murakata C, Saitoh H, Suzuki K, Tamaoki T (1990) Potent selective inhibition of 7-O-methyl-UCN-01 against protein kinase C. J Pharmacol Exp Ther 255:1218
11. Tomaszewski JE, Smith AC (1997) Safety testing of antitumor agents. In Sipes IG, Gandolf AJ, McQueen CA (eds) Comprehensive toxicology, vol 2. Pergamon, New York, p 299
12. Wang Q, Worland PJ, Clark JL, Carlson, BA, Sausville EA (1995) Apoptosis in 7-hydroxy-staurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927
13. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956